A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a metaanalysis

Final STEPP results of prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC)

(2017) E. P. Mitchell et al.   JOURNAL OF CLINICAL ONCOLOGY

Prophylactic use of K1 cream for reducing skin toxicity during cetuximab treatment in patients with metastatic colorectal cancer (mCRC).

(2017) J. Ocvirk et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines

(2011) J. Bernier et al.   ANNALS OF ONCOLOGY

Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors

(2011) Peggy A Wu et al.   CURRENT OPINION IN ONCOLOGY

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion

(2010) K. Potthoff et al.   ANNALS OF ONCOLOGY

Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

(2010) Marc Peeters et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

(2010) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group

(2010) Mario E. Lacouture et al.   SUPPORTIVE CARE IN CANCER

Dermatologic Infections in Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitor Therapy

(2009) R. E. Eilers et al.   JNCI-Journal of the National Cancer Institute

Anti-Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?

(2009) M. Peeters et al.   ONCOLOGIST

Skin toxicities associated with epidermal growth factor receptor inhibitors

(2009) Tianhong Li et al.   Targeted Oncology

A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition

(2008) Andreas Wollenberg et al.   EXPERIMENTAL DERMATOLOGY

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

(2008) Carsten Bokemeyer et al.   JOURNAL OF CLINICAL ONCOLOGY